

Sofia Ramiro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6654212/publications.pdf>

Version: 2024-02-01

504
papers

70,040
citations

1704

104
h-index

663

255
g-index

519
all docs

519
docs citations

519
times ranked

32508
citing authors

#	ARTICLE	IF	CITATIONS
1	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
3	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.9	2,994
4	Rheumatoid arthritis. <i>Lancet</i> , The, 2016, 388, 2023-2038.	13.7	2,989
5	Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1594-1602.	27.0	2,910
6	Infliximab (chimeric anti-tumour necrosis factor $\hat{\pm}$ monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. <i>Lancet</i> , The, 1999, 354, 1932-1939.	13.7	2,266
7	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
8	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637.	0.9	1,711
9	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.9	1,688
10	Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor γ monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1998, 41, 1552-1563.	6.7	1,560
11	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18001.	30.5	1,441
12	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.9	1,429
13	Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. <i>Lancet</i> , The, 2008, 371, 987-997.	13.7	1,269
14	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.9	1,265
15	Diagnosis and Management of Rheumatoid Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1360.	7.4	1,257
16	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 978-991.	0.9	1,220
17	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.9	1,114
18	Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2004, 50, 3432-3443.	6.7	1,080

#	ARTICLE	IF	CITATIONS
19	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
20	New therapies for treatment of rheumatoid arthritis. <i>Lancet, The</i> , 2007, 370, 1861-1874.	13.7	859
21	Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. <i>Arthritis Research</i> , 2005, 7, R796.	2.0	838
22	EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 636-643.	0.9	753
23	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 499-510.	0.9	743
24	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 62-68.	0.9	659
25	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.9	657
26	EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 34-45.	0.9	651
27	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	0.9	609
28	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.9	558
29	EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 804-814.	0.9	504
30	Baricitinib in Patients with Refractory Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2016, 374, 1243-1252.	27.0	499
31	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor $\hat{\pm}$ inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. <i>Lancet, The</i> , 2009, 374, 210-221.	13.7	497
32	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.9	484
33	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 529-535.	0.9	456
34	Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. <i>Arthritis and Rheumatism</i> , 2005, 52, 2625-2636.	6.7	428
35	The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, S100-8.	0.8	417
36	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.9	397

#	ARTICLE	IF	CITATIONS
37	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 909-920.	0.9	394
38	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959.	0.9	393
39	Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. <i>Arthritis and Rheumatism</i> , 2006, 54, 702-710.	6.7	390
40	Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. <i>Nature Reviews Rheumatology</i> , 2015, 11, 276-289.	8.0	372
41	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet</i> , The, 2017, 390, 457-468.	13.7	360
42	Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 811-818.	0.9	325
43	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1012-1019.	0.9	314
44	Inequities in access to biologic and synthetic DMARDs across 46 European countries. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 198-206.	0.9	289
45	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1101-1136.	0.9	277
46	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 16-22.	0.9	275
47	Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1441-1447.	0.9	274
48	2018 update of the EULAR recommendations for the management of hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 16-24.	0.9	273
49	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 516-528.	0.9	270
50	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.9	268
51	Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1455-1461.	0.9	263
52	Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. <i>Arthritis and Rheumatism</i> , 2006, 54, 2784-2792.	6.7	241
53	Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. <i>Lancet</i> , The, 2019, 393, 2303-2311.	13.7	237
54	A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 319-326.	0.9	234

#	ARTICLE	IF	CITATIONS
55	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet, The</i> , 2014, 383, 321-332.	13.7	232
56	Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. <i>RMD Open</i> , 2018, 4, e000612.	3.8	227
57	Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2007, 56, 3226-3235.	6.7	225
58	Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 3-5.	0.9	212
59	Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. <i>Journal of Rheumatology</i> , 2019, 46, 7-18.	2.0	207
60	A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 123-131.	0.9	206
61	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 760-770.	0.9	205
62	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	0.9	204
63	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 638-643.	0.9	203
64	A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. <i>Rheumatology</i> , 2009, 48, 1114-1121.	1.9	198
65	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1113-1136.	0.9	195
66	Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1143-1151.	0.9	187
67	EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1172-1176.	0.9	183
68	Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 64-71.	0.9	183
69	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2018-213030.	0.9	183
70	Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1004-1009.	0.9	179
71	Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 52-59.	0.9	174
72	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 165-174.	0.9	173

#	ARTICLE	IF	CITATIONS
73	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 744-759.	0.9	167
74	The role of biosimilars in the treatment of rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 322-328.	0.9	166
75	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.9	160
76	Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 733-739.	0.9	159
77	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.9	158
78	Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. <i>RMD Open</i> , 2018, 4, e000598.	3.8	155
79	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1589-1595.	0.9	152
80	A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 58-64.	0.9	146
81	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. <i>Lancet</i> , The, 2016, 388, 2763-2774.	13.7	144
82	Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants. <i>Arthritis and Rheumatism</i> , 2011, 63, 43-52.	6.7	141
83	The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 495-502.	0.9	136
84	The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 663-675.	3.3	134
85	Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt – a national health survey. <i>RMD Open</i> , 2016, 2, e000166.	3.8	133
86	Minimal disease activity for rheumatoid arthritis: a preliminary definition. <i>Journal of Rheumatology</i> , 2005, 32, 2016-24.	2.0	132
87	Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1102-1107.	0.9	131
88	Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 518-523.	0.9	130
89	Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1823-1828.	0.9	130
90	The Definition and Measurement of Disease Modification in Inflammatory Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 9-44.	1.9	124

#	ARTICLE	IF	CITATIONS
91	A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 831-839.	0.9	124
92	Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 510-515.	0.9	123
93	Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 995-1003.	0.9	122
94	Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. <i>Rheumatology</i> , 2017, 56, 1479-1483.	1.9	122
95	Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 687-693.	0.9	119
96	Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 114-123.	0.9	118
97	Treat-to-target (T2T) recommendations for gout. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 632-638.	0.9	118
98	Impact of comorbidity on physical function in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 536-541.	0.9	117
99	EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 479-481.	0.9	114
100	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34.	0.9	114
101	Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2107-2116.	0.9	113
102	Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 534-542.	0.9	111
103	Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 381-388.	1.9	109
104	Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1702-1705.	0.9	109
105	Comparative effectiveness and safety of biological treatment options after tumour necrosis factor $\hat{\pm}$ inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1303-1308.	0.9	108
106	Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. <i>Arthritis Research and Therapy</i> , 2014, 16, R56.	3.5	108
107	Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 234-240.	0.9	107
108	Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 778-786.	0.9	104

#	ARTICLE	IF	CITATIONS
109	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.9	102
110	Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. <i>RMD Open</i> , 2017, 3, e000396.	3.8	99
111	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 490-498.	0.9	98
112	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	2.7	97
113	Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1058-1064.	0.9	95
114	The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. <i>European Journal of Health Economics</i> , 2008, 8, 61-86.	2.8	90
115	Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2010-2021.	0.9	90
116	Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. <i>RMD Open</i> , 2015, 1, e000153.	3.8	85
117	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 694-700.	0.9	83
118	Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1190-1196.	0.9	82
119	Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 902-905.	0.9	82
120	Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?. <i>Arthritis and Rheumatism</i> , 2005, 52, 2975-2983.	6.7	77
121	Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. <i>RMD Open</i> , 2019, 5, e001108.	3.8	77
122	Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 546-549.	0.9	76
123	Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: A systematic review. <i>Arthritis Care and Research</i> , 2010, 62, 108-117.	3.4	73
124	Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 369-389.	3.3	73
125	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	5.6	72
126	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1999-2002.	0.9	71

#	ARTICLE	IF	CITATIONS
127	The patient perspective on remission in rheumatoid arthritis: "You've got limits, but you're back to being you again"™. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1004-1010.	0.9	71
128	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. <i>Nature Reviews Rheumatology</i> , 2016, 12, 743-750.	8.0	71
129	Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 293-299.	0.9	71
130	Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1545-1549.	0.9	71
131	The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?. <i>Arthritis Research and Therapy</i> , 2008, 10, 208.	3.5	69
132	Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. <i>RMD Open</i> , 2017, 3, e000397.	3.8	69
133	Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 540-546.	0.9	67
134	Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 418-421.	0.9	67
135	Era of biosimilars in rheumatology: reshaping the healthcare environment. <i>RMD Open</i> , 2019, 5, e000900.	3.8	67
136	Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. <i>Rheumatology</i> , 2016, 55, kev340.	1.9	66
137	Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 171-178.	0.9	66
138	Criteria for early rheumatoid arthritis: From Bayes' law revisited to new thoughts on pathogenesis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1155-1159.	6.7	63
139	Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1479-1485.	0.9	63
140	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 88-93.	0.9	63
141	Risk profiling for a refractory course of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 211-217.	3.4	62
142	The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 855-861.	0.9	61
143	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1290-1297.	0.9	61
144	Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 996-1002.	0.9	60

#	ARTICLE	IF	CITATIONS
145	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 201-208.	0.9	59
146	Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 167-173.	3.4	58
147	Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study. <i>Arthritis Care and Research</i> , 2017, 69, 1606-1611.	3.4	58
148	Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. <i>Rheumatology</i> , 2015, 54, 633-640.	1.9	57
149	Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1310-1319.	0.9	56
150	Prevalence and social burden of active chronic low back pain in the adult Portuguese population: results from a national survey. <i>Rheumatology International</i> , 2016, 36, 183-197.	3.0	55
151	Biosimilars to treat inflammatory arthritis: the challenge of proving identity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1589-1593.	0.9	52
152	Association of Comorbidities in Spondyloarthritis With Poor Function, Work Disability, and Quality of Life: Results From the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study. <i>Arthritis Care and Research</i> , 2018, 70, 1257-1262.	3.4	52
153	Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: a systematic literature review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 886-890.	0.9	51
154	Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. <i>Lancet Rheumatology</i> , The, 2020, 2, e347-e357.	3.9	51
155	Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 874-878.	0.9	49
156	Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. <i>Rheumatology</i> , 2017, 56, 1771-1779.	1.9	49
157	Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises. <i>Journal of Rheumatology</i> , 2018, 45, 1289-1295.	2.0	49
158	Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?. <i>Arthritis Research and Therapy</i> , 2013, 15, R14.	3.5	48
159	Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 371-377.	0.9	48
160	Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 710-720.	1.9	47
161	The need for new classification criteria for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 3333-3336.	6.7	46
162	The importance of reporting disease activity states in rheumatoid arthritis clinical trials. <i>Arthritis and Rheumatism</i> , 2008, 58, 2622-2631.	6.7	46

#	ARTICLE	IF	CITATIONS
163	Reference intervals of spinal mobility measures in normal individuals: the mobility study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1218-1224.	0.9	45
164	Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. <i>Modern Rheumatology</i> , 2020, 30, 36-43.	1.8	44
165	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 453-459.	0.9	43
166	The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2016, 43, 1680-1686.	2.0	42
167	Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 445-452.	0.9	42
168	In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 715-720.	0.9	41
169	Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort. <i>Arthritis Research and Therapy</i> , 2018, 20, 218.	3.5	41
170	Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. <i>RMD Open</i> , 2019, 5, e000585.	3.8	41
171	What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 324-331.	0.9	41
172	Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2017, 69, 1374-1380.	5.6	40
173	Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. <i>Arthritis and Rheumatology</i> , 2017, 69, 728-734.	5.6	39
174	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779.	3.4	39
175	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). <i>RMD Open</i> , 2016, 2, e000221.	3.8	38
176	The effects of structural damage on functional disability in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2038-2045.	0.9	38
177	Spinal Radiographic Progression in Early Axial Spondyloarthritis: Five-Year Results From the <sc>DESIR</sc> Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 1678-1684.	3.4	38
178	Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). <i>Arthritis Research and Therapy</i> , 2015, 17, 157.	3.5	37
179	New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. <i>Rheumatology</i> , 2017, 56, kew390.	1.9	36
180	Patients' experience of shoulder disorders: a systematic review of qualitative studies for the OMERACT Shoulder Core Domain Set. <i>Rheumatology</i> , 2019, 58, 1410-1421.	1.9	36

#	ARTICLE	IF	CITATIONS
181	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878.	0.9	36
182	Work Outcome in Patients With Ankylosing Spondylitis: Results From a 12-Year Followup of an International Study. <i>Arthritis Care and Research</i> , 2016, 68, 544-552.	3.4	35
183	Patient global assessment in psoriatic arthritis – what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. <i>Joint Bone Spine</i> , 2016, 83, 335-340.	1.6	35
184	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. <i>Lupus Science and Medicine</i> , 2020, 7, e000424.	2.7	35
185	The ASAS-OMERACT core domain set for axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1342-1349.	3.4	35
186	Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?. <i>RMD Open</i> , 2015, 1, e000155-e000155.	3.8	34
187	Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 405-411.	0.9	34
188	Impact of Chronic Diseases and Multimorbidity on Health and Health Care Costs: The Additional Role of Musculoskeletal Disorders. <i>Arthritis Care and Research</i> , 2016, 68, 1823-1831.	3.4	33
189	Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 126-132.	0.9	33
190	In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. <i>Arthritis Research and Therapy</i> , 2019, 21, 28.	3.5	33
191	Three handy tips and a practical guide to improve your propensity score models. <i>RMD Open</i> , 2019, 5, e000953.	3.8	33
192	Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1609-1615.	0.9	33
193	I Would Never Take Preventive Medication! Perspectives and Information Needs of People Who Underwent Predictive Tests for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 360-368.	3.4	33
194	Activity assessments in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2008, 20, 306-313.	4.3	32
195	Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review. <i>Journal of Rheumatology</i> , 2016, 43, 607-617.	2.0	32
196	Interferon signals and monocytic sensitization of the interferon- β signaling pathway in the peripheral blood of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 400-408.	6.7	31
197	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1567-1570.	0.9	31
198	Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. <i>Rheumatology</i> , 2016, 55, 1217-1224.	1.9	31

#	ARTICLE	IF	CITATIONS
199	Back to the future: forget ultrasound and focus on clinical assessment in rheumatoid arthritis management. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 18-20.	0.9	31
200	Treat to Target in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 477-485.	1.9	31
201	Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for Psoriatic Arthritis (DAPSA) based on 28 joints?. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1736-1741.	0.9	30
202	Response to: "Comment on: "EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update" by Gossec et al" by Wei et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e139-e139.	0.9	30
203	Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for Psoriatic Arthritis (DAPSA). A brief review. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S48-50.	0.8	30
204	Aspects of validity of the self-administered comorbidity questionnaire in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2014, 53, 1054-1064.	1.9	29
205	When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1497-1498.	0.9	28
206	Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS cohort: a longitudinal study. <i>Rheumatology</i> , 2015, 54, 83-90.	1.9	28
207	Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. <i>RMD Open</i> , 2019, 5, e001040.	3.8	28
208	Work Disability in Axial Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2020, 22, 55.	4.7	27
209	Insights into the treatment of rheumatoid arthritis: A paradigm in medicine. <i>Journal of Autoimmunity</i> , 2020, 110, 102425.	6.5	27
210	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1268-1271.	0.9	26
211	In rheumatoid arthritis, country of residence has an important influence on fatigue: results from the multinational COMORA study. <i>Rheumatology</i> , 2016, 55, 735-744.	1.9	26
212	Hemocytometric characteristics of COVID-19 patients with and without cytokine storm syndrome on the sysmex XN-10 hematology analyzer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 783-793.	2.3	26
213	EpiReumaPt- the study of rheumatic and musculoskeletal diseases in Portugal: a detailed view of the methodology. <i>Acta Reumatológica Portuguesa</i> , 2015, 40, 110-24.	0.2	26
214	Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2671-2679.	5.6	25
215	The OMERACT Core Domain Set for Clinical Trials of Shoulder Disorders. <i>Journal of Rheumatology</i> , 2019, 46, 969-975.	2.0	25
216	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 276-284.	3.4	25

#	ARTICLE	IF	CITATIONS
217	Tumor Necrosis Factor Inhibitors Reduce Spinal Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Longitudinal Analysis From the Alberta Prospective Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 1211-1219.	5.6	25
218	Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 7-12.	0.9	24
219	The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 164.	3.5	24
220	Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA). <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 486-493.	0.9	24
221	Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 203.	3.5	23
222	Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015, 54, 1630-1639.	1.9	23
223	Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1566-1572.	0.9	23
224	Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure. <i>Arthritis Research and Therapy</i> , 2006, 8, R46.	3.5	22
225	Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review. <i>Rheumatology</i> , 2015, 54, 981-993.	1.9	22
226	A psychometric analysis of outcome measures in peripheral spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1302-1307.	0.9	22
227	Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 289-292.	0.9	22
228	Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort. <i>Lupus</i> , 2019, 28, 94-103.	1.6	22
229	Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 709-718.	3.4	22
230	Socioeconomic inequities in perceived health among patients with musculoskeletal disorders compared with other chronic disorders: results from a cross-sectional Dutch study. <i>RMD Open</i> , 2015, 1, e000045-e000045.	3.8	21
231	Work outcome in persons with musculoskeletal diseases: comparison with other chronic diseases & the role of musculoskeletal diseases in multimorbidity. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 10.	1.9	21
232	Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 153-164.	1.9	21
233	Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Na ⁺ -ve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. <i>Rheumatology and Therapy</i> , 2020, 7, 1021-1035.	2.3	21
234	The burden of rheumatoid arthritis and access to treatment: a medical overview. <i>European Journal of Health Economics</i> , 2008, 8, 39-47.	2.8	20

#	ARTICLE	IF	CITATIONS
235	Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. <i>Journal of Rheumatology</i> , 2016, 43, 203-207.	2.0	20
236	Is the Site of Back Pain Related to the Location of Magnetic Resonance Imaging Lesions in Patients With Chronic Back Pain? Results From the Spondyloarthritis Caught Early Cohort. <i>Arthritis Care and Research</i> , 2017, 69, 717-723.	3.4	20
237	Large country differences in work outcomes in patients with RA – an analysis in the multinational study COMORA. <i>Arthritis Research and Therapy</i> , 2017, 19, 216.	3.5	20
238	The Portuguese Society of Rheumatology position paper on the use of biosimilars. <i>Acta Reumatológica Portuguesa</i> , 2014, 39, 60-71.	0.2	20
239	Brief Report: Erosions and Sclerosis on Radiographs Precede the Subsequent Development of Syndesmophytes at the Same Site: A Twelve-Year Prospective Followup of Patients With Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2773-2779.	5.6	19
240	Rheumatology training experience across Europe: analysis of core competences. <i>Arthritis Research and Therapy</i> , 2016, 18, 213.	3.5	19
241	Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis?. <i>Arthritis and Rheumatology</i> , 2019, 71, 382-391.	5.6	19
242	Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?. <i>Arthritis Research and Therapy</i> , 2020, 22, 195.	3.5	19
243	Do Smoking and Socioeconomic Factors Influence Imaging Outcomes in Axial Spondyloarthritis? Five-Year Data From the DESIR Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1855-1862.	5.6	19
244	Addressing Health Literacy Needs in Rheumatology: Which Patient Health Literacy Profiles Need the Attention of Health Professionals?. <i>Arthritis Care and Research</i> , 2021, 73, 100-109.	3.4	19
245	Differences and similarities in rheumatology specialty training programmes across European countries. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1183-1187.	0.9	18
246	How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 782-783.	0.9	18
247	Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1303-1310.	0.9	18
248	Greetings from the editor 2019. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1-2.	0.9	18
249	Greetings from the editor 2020. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1-2.	0.9	18
250	Instrument selection for the ASAS core outcome set for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 763-772.	0.9	18
251	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. <i>RMD Open</i> , 2018, 4, e000756.	3.8	17
252	Disease activity assessment in patients with psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 401-414.	3.3	17

#	ARTICLE	IF	CITATIONS
253	Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid arthritis (RA): Lessons from QUEST RA. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 705-720.	3.3	16
254	Hierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve-Year Data. <i>Arthritis Care and Research</i> , 2015, 67, 1571-1577.	3.4	16
255	EULAR – points to consider™ for the conduction of workforce requirement studies in rheumatology. <i>RMD Open</i> , 2018, 4, e000780.	3.8	16
256	Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. <i>RMD Open</i> , 2018, 4, e000766.	3.8	16
257	Measuring spinal mobility in early axial spondyloarthritis: does it matter?. <i>Rheumatology</i> , 2019, 58, 1597-1606.	1.9	16
258	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 809-819.	2.0	16
259	Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference. <i>RMD Open</i> , 2021, 7, e001654.	3.8	16
260	Fluctuations in patient reported disease activity, pain and global being in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2016, 55, 2014-2022.	1.9	15
261	Patients'™ preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists. <i>Rheumatology</i> , 2017, 56, 68-76.	1.9	15
262	Deriving common comorbidity indices from the MedDRA classification and exploring their performance on key outcomes in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 548-554.	1.9	15
263	Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. <i>RMD Open</i> , 2018, 4, e000755.	3.8	15
264	Combination Therapy for Pain Management in Inflammatory Arthritis: A Cochrane Systematic Review. <i>Journal of rheumatology Supplement</i> , The, 2012, 90, 47-55.	2.2	14
265	Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology. <i>RMD Open</i> , 2016, 2, e000240.	3.8	14
266	Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. <i>Joint Bone Spine</i> , 2020, 87, 449-454.	1.6	14
267	Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. <i>Rheumatology</i> , 2021, 60, 256-262.	1.9	14
268	Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 937-943.	0.9	14
269	Diagnostic use of office-based ultrasound. <i>Arthritis and Rheumatism</i> , 1995, 38, 859-861.	6.7	13
270	Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. <i>RMD Open</i> , 2018, 4, e000602.	3.8	13

#	ARTICLE	IF	CITATIONS
271	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , 2020, 59, 1842-1852.	1.9	13
272	Measures of Adult Shoulder Function. <i>Arthritis Care and Research</i> , 2020, 72, 250-293.	3.4	13
273	EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1116-1123.	0.9	13
274	Greetings from the editor 2021. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1-3.	0.9	13
275	EpiReumaPt Protocol - Portuguese epidemiologic study of the rheumatic diseases. <i>Acta Reumatológica Portuguesa</i> , 2010, 35, 384-90.	0.2	13
276	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. <i>Current Medical Research and Opinion</i> , 2011, 27, 315-325.	1.9	12
277	Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e67-e67.	0.9	12
278	Comparison of Tests for Lumbar Flexion and Hip Function in Patients With and Without Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2015, 67, 538-545.	3.4	12
279	Percentage of progressors in imaging: can we ignore regressors?. <i>RMD Open</i> , 2019, 5, e000848.	3.8	12
280	Assessment of competences in rheumatology training: results of a systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2020, 6, e001330.	3.8	12
281	Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI. <i>RMD Open</i> , 2020, 6, e001145.	3.8	12
282	Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 593-602.	3.4	12
283	2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 65-70.	0.9	12
284	Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. <i>RMD Open</i> , 2021, 7, e001637.	3.8	12
285	Endorsement of the domains of knee and hip osteoarthritis (OA) flare: A report from the OMERACT 2020 inaugural virtual consensus vote from the flares in OA working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 618-622.	3.4	12
286	Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 2815-2825.	1.9	12
287	RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 713-720.	3.0	11
288	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1755-1760.	0.9	11

#	ARTICLE	IF	CITATIONS
289	OP0095â€¦Randomized, Placebo-Controlled Trial To Evaluate Clinical Efficacy and Structure Modifying Properties of Subcutaneous Etanercept (ETN) in Patients with Erosive Inflammatory Hand Osteoarthritis (OA). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 90.3-91.	0.9	11
290	Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice. <i>Human Gene Therapy</i> , 2017, 28, 168-178.	2.7	11
291	Improving the peer review skills of young rheumatologists and researchers in rheumatology: the EMEUNET Peer Review Mentoring Program. <i>RMD Open</i> , 2018, 4, e000619.	3.8	11
292	Which scoring method depicts spinal radiographic damage in early axial spondyloarthritis best? Five-year results from the DESIR cohort. <i>Rheumatology</i> , 2018, 57, 1991-2000.	1.9	11
293	Frequency of Impaired Spinal Mobility in Patients with Chronic Back Pain Compared to Patients with Early Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2018, 45, 1643-1650.	2.0	11
294	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. <i>Journal of Rheumatology</i> , 2019, 46, 1159-1163.	2.0	11
295	Is active sacroiliitis on MRI associated with radiographic damage in axial spondyloarthritis? Real-life data from the ASAS and DESIR cohorts. <i>Rheumatology</i> , 2019, 58, 798-802.	1.9	11
296	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1423-1431.	0.9	11
297	How Do Gastrointestinal or Liver Comorbidities Influence the Choice of Pain Treatment in Inflammatory Arthritis? A Cochrane Systematic Review. <i>Journal of rheumatology Supplement</i> , The, 2012, 90, 74-80.	2.2	10
298	Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 532-537.	0.9	10
299	5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort. <i>RMD Open</i> , 2020, 6, e001093.	3.8	10
300	Disease activity is associated with spinal radiographic progression in axial spondyloarthritis independently of exposure to tumour necrosis factor inhibitors. <i>Rheumatology</i> , 2021, 60, 461-462.	1.9	10
301	Young peopleâ€™s perspectives on patient-reported outcome measures in inflammatory arthritis: results of a multicentre European qualitative study from a EULAR task force. <i>RMD Open</i> , 2021, 7, e001517.	3.8	10
302	Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 214-21.	0.8	10
303	Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. <i>RMD Open</i> , 2018, 4, e000773.	3.8	9
304	Strategies for the assessment of competences during rheumatology training across Europe: results of a qualitative study. <i>RMD Open</i> , 2020, 6, e001183.	3.8	9
305	Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable. <i>Rheumatology</i> , 2021, 60, 638-648.	1.9	9
306	Determinants of the patient global assessment of well-being in early axial spondyloarthritis: 5-year longitudinal data from the DESIR cohort. <i>Rheumatology</i> , 2021, 60, 316-321.	1.9	9

#	ARTICLE	IF	CITATIONS
307	Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001522.	3.8	9
308	COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions. <i>RMD Open</i> , 2021, 7, e001638.	3.8	9
309	Role of vertebral corner inflammation and fat deposition on MRI on syndesmophyte development detected on whole spine low-dose CT scan in radiographic axial spondyloarthritis. <i>RMD Open</i> , 2022, 8, e002250.	3.8	9
310	Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: <sc>Three-Year</sc> Results From a Phase <sc>IIb</sc> Randomized Controlled Trial and Its <sc>Open-Label</sc> Extension Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 1943-1958.	5.6	9
311	In patients with axial spondyloarthritis, inflammation on MRI of the spine is longitudinally related to disease activity only in men: 2 years of the axial spondyloarthritis DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 470-472.	0.9	8
312	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1108-1112.	3.4	8
313	Association of the different types of radiographic damage with physical function in patients with rheumatoid arthritis: analysis of the RAPID trials. <i>RMD Open</i> , 2016, 2, e000219.	3.8	8
314	Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?. <i>RMD Open</i> , 2018, 4, e000648.	3.8	7
315	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1472-1479.	0.9	7
316	SAT0575â€¦Disease Activity in Psoriatic Arthritis (PSA): Defining Remission and Treatment Success Using the Dapsa-Score. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 869.1-869.	0.9	6
317	Multidisciplinary collaboration among young specialists: results of an international survey by the emerging EULAR network and other young organisations. <i>RMD Open</i> , 2020, 6, e001398.	3.8	6
318	Response to: â€˜Correspondence on â€˜Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC studyâ€™â€™ by Calvo-Aranda<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e35-e35.	0.9	6
319	No relationship between bone mineral density and syndesmophyte formation at the same level in the lumbar spine of patients with radiographic axial Spondyloarthritis. <i>RMD Open</i> , 2020, 6, e001391.	3.8	6
320	Mentoring for postdoctoral researchers in rheumatology: the Emerging EULAR Network (EMEUNET) post-doc mentoring programme. <i>RMD Open</i> , 2020, 6, e001139.	3.8	6
321	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 643-644.	3.4	6
322	Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort. <i>RMD Open</i> , 2021, 7, e001685.	3.8	6
323	Low-dose CT hounsfield units: a reliable methodology for assessing vertebral bone density in radiographic axial spondyloarthritis. <i>RMD Open</i> , 2022, 8, e002149.	3.8	6
324	How to deal with missing items in BASDAI and BASFI. <i>Rheumatology</i> , 2014, 53, 374-376.	1.9	5

#	ARTICLE	IF	CITATIONS
325	Reference curves for the Australian/Canadian Hand Osteoarthritis Index in the middle-aged Dutch population. <i>Rheumatology</i> , 2017, 56, kew483.	1.9	5
326	Person-focused care for young people with rheumatic and musculoskeletal diseases: young rheumatologists' and EULAR Young PARE perspectives. <i>RMD Open</i> , 2017, 3, e000514.	3.8	5
327	Equivalence in the Health Assessment Questionnaire (HAQ) across socio-demographic determinants: Analyses within QUEST-RA. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 492-500.	3.4	5
328	Performance of referral strategies for spondyloarthritis: a population-based nationwide study. <i>Rheumatology</i> , 2019, 58, 1086-1094.	1.9	5
329	Which imaging outcomes for axSpA are most sensitive to change? A 5-year analysis of The DESIR Cohort. <i>Arthritis Care and Research</i> , 2020, , .	3.4	5
330	Integrated longitudinal analysis does not compromise precision and reduces bias in the study of imaging outcomes: A comparative 5-year analysis in the DESIR cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1394-1399.	3.4	5
331	Association between individual and country-level socioeconomic factors and work participation in spondyloarthritis including psoriatic arthritis: Analysis of the ASAS-perSpA study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 804-812.	3.4	5
332	Individual-level and country-level socio-economic factors and health outcomes in spondyloarthritis: analysis of the ASAS-perSpA study. <i>Rheumatology</i> , 2022, 61, 2043-2053.	1.9	5
333	CoReumaPt protocol: the Portuguese cohort of rheumatic diseases. <i>Acta Reumatológica Portuguesa</i> , 2012, 37, 18-24.	0.2	5
334	Development of amyloidosis in patients with rheumatoid arthritis under TNF-blocking agents. <i>Clinical Rheumatology</i> , 2011, 30, 869-870.	2.2	4
335	Response to: "2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?" by Misra et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e48-e48.	0.9	4
336	The new editor greets you. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1636-1636.	0.9	4
337	Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients. <i>Rheumatology</i> , 2018, 57, 969-976.	1.9	4
338	Considering new lessons about the use of IL-6 inhibitors in arthritis. <i>Considerations in Medicine</i> , 2018, 2, 7-11.	0.0	4
339	Socio-economic gradients in the presence of musculoskeletal and other chronic diseases: results from a cross-sectional study in the Netherlands. <i>Clinical Rheumatology</i> , 2018, 37, 3173-3182.	2.2	4
340	Inflammation of the sacroiliac joints and spine on MRI predicts structural changes on MRI in axial spondyloarthritis: 5-year data from DESIR. <i>Arthritis Care and Research</i> , 2020, , .	3.4	4
341	What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. <i>Rheumatology</i> , 2021, 60, 5292-5299.	1.9	4
342	Peripheral arthritis and higher disease activity lead to more functional impairment in axial spondyloarthritis: Longitudinal analysis from ESPAXIA. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 553-558.	3.4	4

#	ARTICLE	IF	CITATIONS
343	Three-month and six-month outcomes of patients with COVID-19 associated hyperinflammation treated with short-term immunosuppressive therapy: follow-up of the CHIC study. <i>RMD Open</i> , 2021, 7, e001906.	3.8	4
344	Muscle dysfunction in axial spondylarthritis: the MyoSpA study. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 267-273.	0.8	4
345	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. <i>RMD Open</i> , 2022, 8, e002031.	3.8	4
346	AB0380â€¦Treat-to-target in systemic lupus erythematosus: report from the t2t/sle working party. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A903.2-A903.	0.9	3
347	FRIO498â€¦Outcomes associated with achievement of various treatment targets in patients with psoriatic arthritis receiving adalimumab. , 2017, , .		3
348	Opportunities and challenges in rheumatology research in Central Europe. <i>Arthritis Research and Therapy</i> , 2017, 19, 196.	3.5	3
349	Targeting IL-6: A review of data. <i>Considerations in Medicine</i> , 2018, 2, 12-18.	0.0	3
350	To DAPSA or not to DAPSA? That is not the question. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e61-e61.	0.9	3
351	Which disease activity outcome measure discriminates best in axial spondyloarthritis? A systematic literature review and meta-analysis. <i>Rheumatology</i> , 2020, 59, 3990-3992.	1.9	3
352	Performance and Predictors of Minimal Disease Activity Response in Peripheral Spondyloarthritis Patients Treated With Adalimumab. <i>Arthritis Care and Research</i> , 2020, , .	3.4	3
353	What Do the OMERACT Shoulder Core Set Candidate Instruments Measure? An Analysis Using the Refined International Classification of Functioning, Disability, and Health Linking Rules. <i>Journal of Rheumatology</i> , 2020, 47, 1557-1564.	2.0	3
354	Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001096.	3.8	3
355	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. <i>Journal of Rheumatology</i> , 2020, 47, 796-808.	2.0	3
356	Socio-economic inequalities in occurrence and health care costs in rheumatic and musculoskeletal diseases: results from a Spanish population-based study including 1.9 million persons. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 589-594.	0.8	3
357	Exploring discordance between Health Literacy Questionnaire scores of people with RMDs and assessment by treating health professionals. <i>Rheumatology</i> , 2022, 62, 52-64.	1.9	3
358	Analysis of TNFR2-mediated functions on osteoclast precursor cells. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A35-A36.	0.9	2
359	Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 1732-1736.	1.9	2
360	Neutral lateral fingertip-to-floor distance can be derived from height. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1748-1749.	0.9	2

#	ARTICLE	IF	CITATIONS
361	OP0031...A Phase 2 Study Evaluating the Efficacy and Safety of Subcutaneously Administered Ustekinumab and Guselkumab in Patients with Active Rheumatoid Arthritis Despite Treatment with Methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 76.2-77.	0.9	2
362	Response to: "Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update" by Goswami et al. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e36-e36.	0.9	2
363	Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists. <i>RMD Open</i> , 2017, 3, e000453.	3.8	2
364	Greetings from the editor. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 789-789.	0.9	2
365	Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 188.	3.5	2
366	Response to: "High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab" by Conticini et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e203-e203.	0.9	2
367	Response to: "Correspondence on "Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study" by Charles. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e109-e109.	0.9	2
368	Greetings from the editor. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 677-678.	0.9	2
369	Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1362-1363.	0.9	2
370	EULAR portfolio for Rheumatology training: a EULAR School of Rheumatology initiative. <i>RMD Open</i> , 2021, 7, e001684.	3.8	2
371	FRIO553... "Back to being normal": the patient perspective on remission in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A562.2-A562.	0.9	2
372	Response to: Where are the women "Heroes and Pillars of Rheumatology"? <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e200-e200.	0.9	2
373	Translation and cross-cultural adaptation of the ASAS Health Index and ASAS Environmental Factors Item Set into European Portuguese Language. <i>Acta Reumatológica Portuguesa</i> , 2017, 42, 256-262.	0.2	2
374	Portuguese recommendations for the use of biological therapies in patients with axial spondyloarthritis - 2016 update. <i>Acta Reumatológica Portuguesa</i> , 2017, 42, 209-218.	0.2	2
375	On publication policy, combination therapy, and the European League Against Rheumatism recommendations for the management of rheumatoid arthritis: Comment on the article by Graudal et al. <i>Arthritis and Rheumatism</i> , 2011, 63, 3182-3185.	6.7	1
376	FRIO090... Fulfilling only three of four ACR/EULAR boolean remission criteria is not predictive of subsequent full remission. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 339.3-340.	0.9	1
377	THU0282... Immunoabsorption in Lupus Nephritis: Three Different High Affinity Columns are Equally Effective in Inducing Remission. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A261.2-A261.	0.9	1
378	FRIO047... The Patient Perspective on Absence of Disease Activity in Rheumatoid Arthritis: A Survey to Identify Key Domains of Patient Perceived Remission. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 435.3-436.	0.9	1

#	ARTICLE	IF	CITATIONS
379	AB0075â€¦MTOR: An Unexpected Role on the TNF-Regulated mRNA Transcriptome in Rheumatoid Fibroblast-Like Synoviocytes. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 915.3-916.	0.9	1
380	FRI0393â€¦Cut-Off Values for Intima-Media Thickness of Temporal, Facial and Axillary Arteries in Giant Cell Arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 577.1-577.	0.9	1
381	THU0031â€¦Baseline Characteristics and Treatment Outcomes of Patients Who Achieve Deep Remission in Rheumatoid Arthritis: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 188.2-189.	0.9	1
382	THU0685â€¦Asas health index for patients with spondyloarthritis: translation into portuguese, validation, and reliability. , 2017, , .		1
383	SAT0719-HPRâ€¦â€œand suddenly you are a person at risk of developing rheumatoid arthritis!â€•different perspectives of individuals on predictive testing â€œ results of an international qualitative interview study. , 2017, , .		1
384	Response to: â€œConcerns on glucocorticoid use for Japanese patients with established rheumatoid arthritisâ€™ by Oiwa. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e36-e36.	0.9	1
385	Response to: â€œThe GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studiesâ€™ by Tillet <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e24-e24.	0.9	1
386	Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 315-324.	1.9	1
387	Response to: â€œThe role of temporal artery biopsy in patients with giant cell arteritis is debatedâ€™ by Moiseev et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e32-e32.	0.9	1
388	Response to â€œNeither earlier not late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort studyâ€™ by Moiseev et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2020-219295.	0.9	1
389	Response to: â€œIncreasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritisâ€™ by Bugatti<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e56-e56.	0.9	1
390	Is Methotrexate as Efficacious as Etanercept in Psoriatic Arthritis Patients? Comment on the Article by Mease et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 1227-1229.	5.6	1
391	Comment on: Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable: reply. <i>Rheumatology</i> , 2021, 60, e71-e72.	1.9	1
392	Response to: â€œCorrespondence on â€œHistorically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC studyâ€™â€™ by De Santis<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e112-e112.	0.9	1
393	Response to: â€œCorrespondence on â€œHistorically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC studyâ€™â€™ by Charles. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e110-e110.	0.9	1
394	FRI0602â€¦Eular â€œpoints to considerâ€™ for the conduction of workforce requirement studies in rheumatology. , 2018, , .		1
395	SAT0733-HPRâ€¦Dutch recommendations for physical therapy in axial spondyloarthritis (AXSPA). , 2018, , .		1
396	THU0586â€¦ESTABLISHING THE KEY COMPONENTS OF A EULAR PORTFOLIO FOR TRAINING IN RHEUMATOLOGY: A EULAR SCHOOL OF RHEUMATOLOGY INITIATIVE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 535.1-535.	0.9	1

#	ARTICLE	IF	CITATIONS
397	Determinants of the physician global assessment of disease activity and influence of contextual factors in early axial spondyloarthritis.. Arthritis Care and Research, 2020, , .	3.4	1
398	Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools. Clinical and Experimental Rheumatology, 2020, 38, 1056-1067.	0.8	1
399	EMerging EULAR NETwork (EMEUNET): a remarkable foundation for the future. RMD Open, 2021, 7, e001962.	3.8	1
400	Interleukin-6 is not a crucial regulator in tumour necrosis factor-mediated bilateral sacroiliitis. Annals of the Rheumatic Diseases, 2010, 69, A49-A50.	0.9	0
401	Apoptosis and the subsequent generation of autoantigens as initial triggers in the pathogenesis of experimental autoimmune arthritis. Annals of the Rheumatic Diseases, 2010, 69, A60-A60.	0.9	0
402	Class effects of tyrosine kinase inhibitors on osteoclastogenesis in vitro. Annals of the Rheumatic Diseases, 2011, 70, A80-A80.	0.9	0
403	Marine oil supplements for rheumatoid arthritis. The Cochrane Library, 2012, , .	2.8	0
404	AB0127â€¦Arthritis in a model for systemic lupus: involvement of joints, inner organs and course of autoantibodies in pristane-induced lupus.. Annals of the Rheumatic Diseases, 2013, 72, A824.2-A824.	0.9	0
405	SAT0057â€¦Functional impairment in an animal model for rheumatoid arthritis assessed as changes in gait is due to joint destruction but not synovial inflammation per SE. Annals of the Rheumatic Diseases, 2013, 71, 489.2-489.	0.9	0
406	A9.9â€¦Treatment with BGP-15, a Novel Insulin Sensitiser Attenuates Collagen-Induced Arthritis in DBA/1 Mice. Annals of the Rheumatic Diseases, 2013, 72, A67.2-A68.	0.9	0
407	AB0174â€¦Muscle wasting in HTNFTG mice; an animal model for rheumatoid arthritis; due to increased cathepsin I expression. Annals of the Rheumatic Diseases, 2013, 71, 647.11-647.	0.9	0
408	OP0201-HPRâ€¦Development of user- focused standards of care for rheumatoid arthritis the www.eumusc.net project - work package 5. Annals of the Rheumatic Diseases, 2013, 71, 123.1-123.	0.9	0
409	FRI0432â€¦Comparison of tests for lumbar flexion and hip function in patients with axial spondyloarthritis and in healthy controls. Annals of the Rheumatic Diseases, 2013, 72, A521.1-A521.	0.9	0
410	THU0018â€¦Discrimination Analysis of Multiple Genetic Risk Markers Associated with Rheumatoid Arthritis in Slovakia. Annals of the Rheumatic Diseases, 2013, 72, A170.2-A170.	0.9	0
411	THU0559â€¦Patient Education, Disease Activity and Physical Function. Can we be more Targeting? A Cross Sectional Study among People with RA, PsA and Hand OA. Annals of the Rheumatic Diseases, 2013, 72, A353.2-A353.	0.9	0
412	FRI0082â€¦Radiographic progression in rheumatoid arthritis in the 21st century. Annals of the Rheumatic Diseases, 2013, 72, A396.3-A397.	0.9	0
413	AB0185â€¦Clinical joint involvement is decisive for radiographic progression. Annals of the Rheumatic Diseases, 2013, 72, A842.2-A842.	0.9	0
414	SAT0030â€¦Quality Indicators (QIS) in Rheumatoid Arthritis (RA) in Clinical Practice: Results from Measurement of Efficacy of Treatment in The ERA of Outcome in Rheumatology (Meteor) Database. Annals of the Rheumatic Diseases, 2013, 72, A589.3-A590.	0.9	0

#	ARTICLE	IF	CITATIONS
415	FRI0270â€¦Development of systemic lupus-like disease in regulatory T cells (TREG)-deficient scurfy mice.. Annals of the Rheumatic Diseases, 2013, 72, A465.3-A466.	0.9	0
416	THU0094â€¦Treatment with BGP-15, a Novel Insulin Sensitizer Attenuates Collagen-Induced Arthritis in DBA/1 Mice. Annals of the Rheumatic Diseases, 2013, 72, A194.3-A195.	0.9	0
417	FRI0488-HPRâ€¦Are occupational therapy interventions included in the most commonly used european clinical-practice guidelines for the management of osteoarthritis?. Annals of the Rheumatic Diseases, 2013, 71, 754.1-754.	0.9	0
418	SAT0053â€¦Persistence of Subclinical Joint Activity in Rheumatoid Arthritis Joints. Annals of the Rheumatic Diseases, 2014, 73, 608.2-608.	0.9	0
419	OPO284â€¦Mtor Plays A Decisive Role in the Rheumatoid Mesenchymal Tissue Response to Inflammation. Annals of the Rheumatic Diseases, 2014, 73, 169.2-169.	0.9	0
420	THU0479â€¦Dheas-Associated Genotypes Contribute to Adrenal Androgen Hypofunction in RA. Annals of the Rheumatic Diseases, 2014, 73, 349.1-349.	0.9	0
421	A1.80â€¦Alterations in gait profile and bone marrow inflammation before the onset of collagen-induced arthritis. Annals of the Rheumatic Diseases, 2014, 73, A35.2-A35.	0.9	0
422	OPO298â€¦The Role of CD11c+ Dendritic Cells in Inflammatory Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 174.4-175.	0.9	0
423	AB0178â€¦Characterization of CD4+ T Cell Response and Effects of Regulatory T Cells in Pristane Induced Lupus (PIL). Annals of the Rheumatic Diseases, 2014, 73, 861.4-862.	0.9	0
424	AB0273â€¦Personal Factors Important to People with Rheumatoid Arthritis and their Coverage by Patient-Reported Outcome Measures: Table 1.. Annals of the Rheumatic Diseases, 2014, 73, 894.3-894.	0.9	0
425	A1.24â€¦Cilengitide reduces pannus formation and bone erosions in collagen induced arthritis. Annals of the Rheumatic Diseases, 2014, 73, A10.1-A10.	0.9	0
426	SAT0238â€¦Gender-Attributable Differences in Outcome of Ankylosing Spondylitis: Long-Term Results from the Outcome in Ankylosing Spondylitis International Study. Annals of the Rheumatic Diseases, 2015, 74, 744.2-745.	0.9	0
427	SAT0637-HPRâ€¦Impairment in the Activities of Daily Living in Older Adults with and Without Osteoporosis, Osteoarthritis and Chronic Back Pain: Results of a Population-Based Cross-Sectional Study. Annals of the Rheumatic Diseases, 2015, 74, 1334.2-1334.	0.9	0
428	SAT0566â€¦Impact of Disease Management by Rheumatologists and Dermatologists on Patients' Attitude Toward Medication in Psoriatic Arthritis: Results from the Global Align Study. Annals of the Rheumatic Diseases, 2015, 74, 865.2-866.	0.9	0
429	FRI0234â€¦Spinal Radiographic Progression in Early Axial Spondyloarthritis: Data from the Desir Cohort. Annals of the Rheumatic Diseases, 2015, 74, 509.2-509.	0.9	0
430	AB0790â€¦Which Score to Use for Radiographic Damage Assessment of the Spine in (Early) Axial Spondyloarthritis? Two-Year Data From the Desir Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1163.2-1163.	0.9	0
431	THU0103â€¦Differences in Patients with Rheumatoid Arthritis who Achieved DAS Remission or SDAI Remission but not Boolean Remission. Annals of the Rheumatic Diseases, 2015, 74, 230.1-230.	0.9	0
432	SAT0356â€¦Predictive Utility of Anti-Citrullinated Peptide Antibodies and Rheumatoid Factor â€œ a Retrospective Data Analysis. Annals of the Rheumatic Diseases, 2015, 74, 788.1-788.	0.9	0

#	ARTICLE	IF	CITATIONS
433	Response to “Dual training in general internal medicine and rheumatology: the Irish context” by Dr Sheane. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e56-e56.	0.9	0
434	OP0185“...Significant Clinical Improvement and Reduction of Severe Flares Following Administration of an IL-6 Monoclonal Antibody in Systemic Lupus Erythematosus (SLE) Subjects with High Disease Activity. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 141.2-142.	0.9	0
435	THU0041“...Large Country Differences in Work Outcomes in Patients with RA “ An Analysis in The Multinational Study Comora. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 192.2-192.	0.9	0
436	THU0403“...Performance of Modified Minimal Disease Activity (MDA) Criteria in Patients with Peripheral Spondyloarthritis: Post-Hoc Analysis of Ability-2. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 334.1-334.	0.9	0
437	FRI0133“...Understanding Anemia in Rheumatoid Arthritis: The Association of Hemoglobin and Hcpidin Levels with Clinical Disease Activity and Acute Phase Response. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 476.1-476.	0.9	0
438	AB0135“...Decreased Lupus Manifestations in Pristane-Induced Microrna 155-Deficient Mice. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 943.1-943.	0.9	0
439	FRI0585“...Importance and Level of Implementation of The EULAR/EUMUSC.net Standards of Care for RA in The Netherlands: Similarities and Discordance between Patients and Health Care Professionals. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 653.3-654.	0.9	0
440	SAT0446“...Reference Curves for The Australian/canadian Hand Osteoarthritis Index (AUSCAN) in The General Population. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 833.1-833.	0.9	0
441	SAT0081“...The Diagnostic and Predictive Value of Anti-Acetylated Peptide Antibodies (AAPA) in Rheumatoid Arthritis Patients Starting Their First Dmard Treatment on Methotrexate: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 694.1-694.	0.9	0
442	SAT0050“...Resident Non-Classical Monocytes Are Critically Important for Tissue Destruction in Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 681.3-682.	0.9	0
443	SAT0525“...The Use of Analgesic and Other Pain Relief Drugs To Manage Chronic Low Back Pain “ Results from A National Survey: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 859.2-859.	0.9	0
444	FRI0582“...Fluctuating Levels of Rheumatoid Factor Predict Progression of Rheumatoid Arthritis, but Not Independent of Disease Activity. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 652.2-653.	0.9	0
445	AB0136“...In Vitro Induced Regulatory T-Cells Can Reduce Severity of Lupus Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 943.2-943.	0.9	0
446	THU0598“...Variations in Policies and Social Security Regulations for Patients with Rheumatoid Arthritis That Experience Restrictions in Work Participation: Results from A Survey across 44 Countries of The European Region. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 408.2-408.	0.9	0
447	THU0628“...Socio-Economically Deprived Patients Have A Higher Likelihood for Having Any Type of Rheumatic and Musculoskeletal Diseases and Have Higher Healthcare Costs - Results from A Population-Based Administrative Database Including 1.9 Million Persons (Basque Country, Spain). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 420.3-421.	0.9	0
448	THU0148“...Economic Considerations and Patients' Preferences Affect Treatment Selection for Rheumatoid Arthritis Patients: A Discrete Choice Experiment among European Rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 235.2-235.	0.9	0
449	Response to: “The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis” by PiriÅ <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e50-e50.	0.9	0
450	FRI0430“...Dual trajectories of disease activity and health-related quality of life in patients with ankylosing spondylitis. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
451	OP0002â€¦Multicriteria decision analysis for developing new classification criteria for systemic lupus erythematosus. , 2017, , .		0
452	AB1240-HPRâ€¦Patients' dogma, number of swollen joints and physicians' and patients' age predict non-adherence to medicines and non-pharmacological interventions in rheumatoid arthritis â€œ a mixed methods study. , 2017, , .		0
453	FRIO479â€¦Predictors of long-term modified minimal disease activity response in peripheral spondyloarthritis patients treated with adalimumab. , 2017, , .		0
454	THU0590â€¦The use of a portfolio among young rheumatologists: results of an emeunet survey. , 2017, , .		0
455	FRIO108â€¦Time to first treatment is associated with a refractory course of rheumatoid arthritis. , 2017, , .		0
456	THU0233â€¦In vitro induced regulatory t-cells can ameliorate severity of pristane induced lupus (PIL). , 2017, , .		0
457	OP0199-PAREâ€¦Support to stay employed and social security arrangements for work disability due to ra â€œ perceptions of patients with ra and rheumatologists in 31 european countries. , 2017, , .		0
458	SAT0515â€¦Sonographic and clinical examination of tendon involvement in hand osteoarthritis. , 2017, , .		0
459	FRIO219â€¦Association between conversion to ACPA/RF seronegative status and clinical outcomes following treatment with abatacept in combination with methotrexate compared with methotrexate alone in patients with early rheumatoid arthritis and poor prognostic indicators. , 2017, , .		0
460	OP0070â€¦The role of individual and country-level socio-economic factors in work participation in patients with spondyloarthritis across 22 countries worldwide: results from the comospa study. , 2017, , .		0
461	THU0602â€¦Worker productivity loss remains a major issue for patients with inflammatory arthritis and osteoarthritis: results from the international eular-pro worker productivity study. , 2017, , .		0
462	AB1245-HPRâ€¦New health technologies and lifestyle management for patients with osteoarthritis. , 2017, , .		0
463	FRIO688â€¦Prera (predicting rheumatoid arthritis): preliminary findings from an on-going prospective study of seropositive and seronegative individuals and their risk for developing ra. , 2017, , .		0
464	P072â€¦Irf1 is critical for the inflammatory gene expression in fibroblast-like synoviocytes. , 2018, , .		0
465	P025â€¦The diagnostic and prognostic value of autoantibodies in rheumatoid arthritis. , 2018, , .		0
466	THU0185â€¦The value of adalimumab trough levels and clinical assessments in predicting clinical response in patients with established rheumatoid arthritis and an inadequate response to methotrexate. , 2018, , .		0
467	THU0272â€¦Which scoring method depicts spinal radiographic damage in (EARLY) axial spondyloarthritis best? five-year results from the desir cohort. , 2018, , .		0
468	IL-6: To immunity and beyond. Considerations in Medicine, 2018, 2, 19-23.	0.0	0

#	ARTICLE	IF	CITATIONS
469	O85â€fWorker productivity loss remains a major issue for patients with inflammatory arthritis and osteoarthritis: results from an international worker-productivity study. <i>Rheumatology</i> , 2018, 57, .	1.9	0
470	THU0464Bâ€...IS THERE AN ASSOCIATION BETWEEN METABOLIC SYNDROME AND SEVERITY OF HAND OSTEOARTHRITIS? RESULTS FROM A NATIONWIDE STUDY. , 2019, , .		0
471	P114â€...Tissue regeneration and bone repair upon TNF blockade in experimental arthritis. , 2019, , .		0
472	P122â€...Important role of dendritic cells in inflammatory arthritis. , 2019, , .		0
473	OP0034â€...DO SMOKING AND SOCIO-ECONOMIC FACTORS INDEPENDENTLY INFLUENCE IMAGING OUTCOMES IN AXIAL SPONDYLOARTHRITIS? FIVE-YEAR DATA FROM THE DESIR COHORT. , 2019, , .		0
474	THU0642â€...EULAR POINTS TO CONSIDER FOR THE DEVELOPMENT, EVALUATION AND IMPLEMENTATION OF MOBILE HEALTH APPLICATIONS FOR SELF-MANAGEMENT IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES. , 2019, , .		0
475	SAT0162â€...A POOLED ANALYSIS OF 1-YEAR CLINICAL OUTCOMES AMONG 6-MONTH RESPONDERS AND NON-RESPONDERS FROM THREE RANDOMISED CONTROLLED STUDIES OF TNF INHIBITOR BIOSIMILARS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
476	THU0403â€...AXIAL SPONDYLOARTHRITIS INDUCES MUSCLE DISFUNCTION, THE ROLE OF BODY COMPOSITION PARAMETERS: MYOSPA STUDY. , 2019, , .		0
477	Marine oil supplements for rheumatoid arthritis. <i>The Cochrane Library</i> , 2019, , .	2.8	0
478	Response to: â€Reactive arthritis, a missing link: comment on the recent article from Sepriano<i>et al</i>â€™ by Zeidler and Hudson. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e41-e41.	0.9	0
479	Response to: â€Correspondence on â€Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC studyâ€™â€™ by Kaklamanos<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e135-e135.	0.9	0
480	POS0953â€...PERIPHERAL ARTHRITIS AND HIGHER DISEASE ACTIVITY LEAD TO MORE FUNCTIONAL IMPAIRMENT IN AXIAL SPONDYLOARTHRITIS: LONGITUDINAL ANALYSIS FROM ESPAXIA. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 740.2-741.	0.9	0
481	POS0924â€...PREDICTORS OF 1-YEAR TREATMENT RESPONSE AMONG UPADACITINIB-TREATED PATIENTS WITH ANKYLOSING SPONDYLITIS: A POST HOC ANALYSIS OF SELECT-AXIS 1. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 723-724.	0.9	0
482	POS0299â€...SOCIOECONOMIC BACKGROUND IS ASSOCIATED WITH DISCORDANCE BETWEEN HEALTH LITERACY OF PEOPLE WITH RMDs AND ASSESSMENT OF HEALTH LITERACY BY THEIR TREATING HEALTH PROFESSIONAL. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 374.2-375.	0.9	0
483	POS0181â€...HOW FIT ARE THE SOCIAL SUPPORT INSTRUMENTS USED IN RMDs: A SYSTEMATIC REVIEW OF VALIDATION STUDIES. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 304.1-304.	0.9	0
484	OP0250â€...MRI VERTEBRAL CORNER INFLAMMATION AND FAT DEPOSITION ARE ASSOCIATED WITH WHOLE SPINE LOW DOSE CT DETECTED SYNDESMOPHYTES: A MULTILEVEL ANALYSIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 152.1-153.	0.9	0
485	Response to: â€Correspondence on â€Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC studyâ€™â€™ by Klopfenstein et al. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-220787.	0.9	0
486	OP0323â€...Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? data from the spondyloarthritis caught early cohort. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
487	FRI0172â€¦Inflammation on mri of the sacroiliac joints is highly predictive of structural damage in axial spondyloarthritis patients in clinical practice: data from the asas and desir cohorts. , 2018, , .		0
488	FRI0174â€¦Spinal radiographic progression in early axial spa: 5-year data from the desir cohort. , 2018, , .		0
489	FRI0179â€¦Integrated longitudinal analysis increases precision and reduces bias: a comparative 5-year analysis in the desir cohort. , 2018, , .		0
490	FRI0171â€¦Which imaging outcomes for axspa are most sensitive to change? a 5-year analysis of the desir cohort. , 2018, , .		0
491	FRI0121â€¦Characteristics of patients with early rheumatoid arthritis who have a delayed response to treatment with methotrexate in monotherapy or in combination with adalimumab. , 2018, , .		0
492	FRI0567â€¦The diagnostic value of autoantibody isotypes in rheumatoid arthritis. , 2018, , .		0
493	THU0239â€¦Progression of structural damage on mri of the spine and sacroiliac joints in patients with axial spondyloarthritis is limited: the 5 â€“year results in the desir cohort. , 2018, , .		0
494	SAT0100â€¦The determinants of refractory rheumatoid arthritis. , 2018, , .		0
495	THU0063â€¦Cd11c+ dendritic cells in inflammatory arthritis. , 2018, , .		0
496	AB1245â€¦Effects of a workplace-centred counselling of individuals with musculoskeletal complaints: a prospective cohort study. , 2018, , .		0
497	OPO246â€¦Inflammation on mri of spine and sacroiliac joints is highly predictive of structural damage in axial spondyloarthritis: the 5 years data of the desir cohort. , 2018, , .		0
498	FRI0259â€¦In vitro induced regulatory t-cells can ameliorate severity of pristane induced lupus (PIL). , 2018, , .		0
499	THU0583â€¦STRATEGIES FOR ASSESSMENT OF COMPETENCES DURING RHEUMATOLOGY TRAINING ACROSS EUROPE: RESULTS OF A QUALITATIVE STUDY.. Annals of the Rheumatic Diseases, 2020, 79, 533.1-534.	0.9	0
500	OPO315â€¦WHICH RESPONSE OR STATUS CRITERION DISCRIMINATES BEST IN AXSPA?. Annals of the Rheumatic Diseases, 2020, 79, 194.1-195.	0.9	0
501	Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive?. Acta ReumatolÃ³gica Portuguesa, 2011, 36, 234-42.	0.2	0
502	Obesity and diabetes are associated with disability in women with hand osteoarthritis. Results from the EpiReumaPt nationwide study. Acta ReumatolÃ³gica Portuguesa, 2021, 46, 208-217.	0.2	0
503	Muscle dysfunction in axial spondylarthritis: the MyoSpA study. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
504	The role of muscle in the susceptibility and progression of axial Spondyloarthritis: The MyoSpA Study Protocol.. Acta ReumatolÃ³gica Portuguesa, 2021, 46, 342-349.	0.2	0